
Claims

1. A pharmaceutical formulation comprising (i) a granule containing a compound represented by formula (I) or a salt thereof:



(I)

and (ii) a disintegrating agent, wherein the granule has a mean particle diameter of 150 μm or more and 300 μm or less, wherein the bulk density of the granule is 0.5 g/ml or more and the tapping density is 0.6 g/ml or more, and wherein the compound represented by formula (I) or a salt thereof is contained in an amount of 140 mg to 190 mg in terms of the free form per unit formulation.

2. The formulation of claim 1, wherein the bulk density of 0.6 g/ml or more and the tapping density of 0.7 g/ml or more.

3. The formulation of claim 1 or 2, wherein the upper limit of the bulk density and the tapping density are 1.0g/ml.

4. The formulation of any of claims 1-3, wherein the granule has a mean particle diameter of 200 μm or more.

5. The formulation of any of claims 1-4, wherein the disintegrating agent (ii) is contained in an amount of 5 wt% or more.

6. The formulation of any of claims 1-5, wherein the disintegrating agent (ii) is contained in an amount of 7.5 wt% or more.

7. The formulation of any of claims 1-6, wherein the disintegrating agent (ii) is selected from sodium starch glycolate, low-substituted hydroxypropylcellulose, carmellose calcium, sodium hydrogen carbonate, pregelatinized starch, sodium chloride, corn starch, croscarmellose sodium, crystalline cellulose, silicic anhydride and carmellose.

8. The formulation of any of claims 1-7, wherein the granule contains a disintegrating agent therein.

9. The formulation of claim 8, wherein the disintegrating agent is selected from sodium starch glycolate, low-substituted hydroxypropylcellulose, carmellose calcium,

sodium hydrogen carbonate, pregelatinized starch, sodium chloride, corn starch, croscarmellose sodium, crystalline cellulose, silicic anhydride and carmellose.

10. The formulation of any of claims 1-9, wherein the granule contains a solubilizing agent therein.

11. The formulation of claim 10, wherein the solubilizing agent is sodium lauryl sulfate.

12. The formulation of any of claims 1-11, wherein the granule contains a binder therein.

13. The formulation of claim 12, wherein the binder is hydroxypropylcellulose.

14. The formulation of any of claims 1-13, wherein the compound represented by formula (I) is 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11 -dihydro-5H-benzo[b]carbazole-3-carbonitrile.

15. The formulation of any of claims 1-14, wherein the compound represented by formula (I) or a salt thereof is contained in an amount of 60 mg to 240 mg in terms of the free form per unit formulation.